These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15365293)

  • 1. Clinical trials. Lipid-lowering therapy and postoperative complications.
    DeSilvey DL
    Am J Geriatr Cardiol; 2004; 13(5):278. PubMed ID: 15365293
    [No Abstract]   [Full Text] [Related]  

  • 2. Severely frail elderly patients do not need lipid-lowering drugs.
    Mallery LH; Moorhouse P; McLean Veysey P; Allen M; Fleming I
    Cleve Clin J Med; 2017 Feb; 84(2):131-142. PubMed ID: 28198686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)].
    Wascher TC; Paulweber B; Toplak H; Saely CH; Drexel H; Föger B; Hoppichler F; Stulnig T; Stingl H; Clodi M;
    Wien Klin Wochenschr; 2019 May; 131(Suppl 1):136-138. PubMed ID: 30980157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 5. Consumption of serum lipid-reducing drugs in Serbia compared with Scandinavian countries: a population-based study, 2004-2008.
    Sabo A; Tomić Z; Stilinović N; Milijašević B; Mikov M; Vukmirović S; Horvat O
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):45-9. PubMed ID: 20938914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis.
    Dykun I; Mincu R; Hendricks S; Balcer B; Totzeck M; Rassaf T; Mahabadi AA
    Eur J Prev Cardiol; 2020 Oct; 27(15):1675-1678. PubMed ID: 31357886
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommendations of the second Indo-U.S. health summit on prevention and control of cardiovascular disease among Asian Indians.
    Enas EA; Singh V; Munjal YP; Gupta R; Patel KC; Bhandari S; Agarwal AK; Joshi SR; Anoop M; Prabhakaran D; Shah B; Reddy S; Sharma B; Trehan N; Yavagal ST; Kasliwal RR;
    Indian Heart J; 2009; 61(3):265-74. PubMed ID: 20503833
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.
    Butters J; Brown A; Griffith L; Kim S; Nicholls SJ
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is aggressive lipid-lowering effective and safe in the older adult?
    LaRosa JC
    Clin Cardiol; 2005 Sep; 28(9):404-7. PubMed ID: 16250262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering therapy in low-risk patients.
    Pearson TA
    JAMA; 1998 May; 279(20):1659-61. PubMed ID: 9613918
    [No Abstract]   [Full Text] [Related]  

  • 11. JCL roundtable: lipid-lowering drugs in those older than 75 years of age.
    Brown WV; Bittner VA; McKenney JM; Ziajka PE
    J Clin Lipidol; 2014; 8(6):533-541. PubMed ID: 25499934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin added to statins for cardiovascular disease.
    Kolber MR; Ivers N; Allan GM
    Can Fam Physician; 2012 Aug; 58(8):842. PubMed ID: 22893335
    [No Abstract]   [Full Text] [Related]  

  • 13. All at sea: new lipid-lowering drug trials continue to disappoint.
    Wierzbicki AS
    Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438
    [No Abstract]   [Full Text] [Related]  

  • 14. The application of evidence-based principles of care in older persons (issue 2): management of lipid disorders.
    Zarowitz BJ; Aronow WS; Hollenack K; O'Shea T
    J Am Med Dir Assoc; 2006 Mar; 7(3):173-9. PubMed ID: 16503311
    [No Abstract]   [Full Text] [Related]  

  • 15. From the editor: drugs, genes, and lipoproteins.
    Brown WV
    J Clin Lipidol; 2014; 8(6):529-530. PubMed ID: 25499933
    [No Abstract]   [Full Text] [Related]  

  • 16. [Risk score for diabetic patients. Is really necessary?].
    Mostaza JM; Lahoz C
    Med Clin (Barc); 2006 Apr; 126(13):495-6. PubMed ID: 16624229
    [No Abstract]   [Full Text] [Related]  

  • 17. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
    Duntas L; Kolovou G
    Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?
    Kostapanos MS; Katsiki N; Elisaf MS; Mikhailidis DP
    Curr Vasc Pharmacol; 2012 Mar; 10(2):173-7. PubMed ID: 22250844
    [No Abstract]   [Full Text] [Related]  

  • 19. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 20. Implications of LDL subclass B in patients at cardiovascular risk.
    Moredich C; Kark D; Keresztes P
    Nurse Pract; 2005 Jul; 30(7):16-8, 23, 26, passim; quiz 29-31. PubMed ID: 16021026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.